RWA
MYGN icon

Redhawk Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

Redhawk Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,205
Closed -$710K – 196
2022
Q3 		$710K Buy
37,205
+2,525
+7% +$57.9K 0.3% 93
2022
Q2 		$630K Buy
34,680
+3,018
+10% +$62.7K 0.29% 96
2022
Q1 		$798K Buy
31,662
+15,635
+98% +$400K 0.21% 84
2021
Q4 		$442K Buy
16,027
+4,072
+34% +$118K 0.11% 126
2021
Q3 		$386K Buy
+11,955
New +$397K 0.11% 132

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Redhawk Wealth Advisors's MYGN Position: Q4 2022 in Review

Redhawk Wealth Advisors sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 37,205 shares — an estimated $710K sold.

Redhawk Wealth Advisors first reported a position in MYGN in Q3 2021 and held it in 5 quarters. The position peaked at $798K in Q1 2022. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

  • Redhawk Wealth Advisors reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
  • Redhawk Wealth Advisors sold 37,205 Myriad Genetics shares in Q4 2022, an estimated $710K.
  • Redhawk Wealth Advisors first reported a position in Myriad Genetics in Q3 2021 and held it in 5 quarters.
  • Redhawk Wealth Advisors's Myriad Genetics position peaked at $798K in Q1 2022.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Redhawk Wealth Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.